Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
11/16/2023 | $45.00 → $53.00 | Neutral → Outperform | Robert W. Baird |
9/5/2023 | $62.00 | Hold → Buy | Argus |
7/20/2023 | $43.00 | Equal Weight | Wells Fargo |
7/5/2023 | $45.00 | Neutral | JP Morgan |
6/14/2023 | $45.00 → $44.00 | Buy → Hold | Jefferies |
5/22/2023 | $90.00 → $45.00 | Overweight → Neutral | JP Morgan |
5/15/2023 | $55.00 → $29.00 | Buy → Hold | Deutsche Bank |
5/8/2023 | $28.00 | Neutral → Underperform | BofA Securities |
Q1'25 net revenue of $1.02 billion increased 4% as reported and in constant currency(1), compared to Q1'24. Q1'25 net revenue, excluding COVID revenue of ~$30 million in Q1'25 and ~$100 million in Q1'24, increased 13% compared to Q1'24. Q1'25 net loss of $(129) million. Q1'25 Adjusted EBITDA(1) of $125 million increased 11% as reported, or 10% in constant currency, compared to Q1'24. (1) See "Non-GAAP Financial Measures" below and the GAAP to non-GAAP reconciliation provided later in this release. Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the first quarter of fisc
Committed to Continuing to Serve Customers and Patients as a Leading Global, Independent, Full-Service CDMO Post-Close Alessandro Maselli to Remain President and CEO of Catalent Post-Close Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today issued the following open letter to customers: To Catalent's Valued Customers, I want to correct a few key inaccuracies that have been reported in the press regarding Novo Holdings' pending acquisition of Catalent and reiterate that we are, and will continue to be, driven by our mission to develop, manufacture and supply products that help people live better and healthier li
Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, announced today that it has entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset, NJ to Ardena, a Contract Development and Manufacturing Organization (CDMO) with locations in Belgium, Spain, the Netherlands and Sweden. Financial details of the agreement, which is expected to close in early 2025, have not been disclosed. The Somerset facility also houses Catalent's corporate headquarters, which in the near term will remain at the Somerset site during a transition period before shifting to a new locati
SC 13G/A - Catalent, Inc. (0001596783) (Subject)
SC 13G/A - Catalent, Inc. (0001596783) (Subject)
SC 13G/A - Catalent, Inc. (0001596783) (Subject)
Q1'25 net revenue of $1.02 billion increased 4% as reported and in constant currency(1), compared to Q1'24. Q1'25 net revenue, excluding COVID revenue of ~$30 million in Q1'25 and ~$100 million in Q1'24, increased 13% compared to Q1'24. Q1'25 net loss of $(129) million. Q1'25 Adjusted EBITDA(1) of $125 million increased 11% as reported, or 10% in constant currency, compared to Q1'24. (1) See "Non-GAAP Financial Measures" below and the GAAP to non-GAAP reconciliation provided later in this release. Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the first quarter of fisc
Q4'24 net revenue of $1.30 billion increased 23% as reported, or 24% in constant currency, compared to Q4'23. Organic, constant-currency net revenue increased 24%, compared to Q4'23. Q4'24 net revenue, excluding COVID-related revenue of ~$70 million in Q4'23 and ~$30 million in Q4'24, increased 29% compared to Q4'23. Fiscal 2024 net revenue of $4.38 billion increased 3% as reported, or 2% in constant currency, compared to fiscal 2023. Organic, constant-currency net revenue increased 1% compared to FY'23. FY'24 net revenue, excluding COVID-related revenue of ~$630 million in FY'23 and ~$260 million in FY'24, increased 13% compared to FY'23. Q4'24 net earnings of $23 million
Q3'24 net revenue of $1.07 billion increased 4% as reported, or 3% in constant currency(1), compared to Q3'23. Q3'24 net revenue, excluding COVID-related revenue of ~$120 million in Q3'23 and ~$60 million in Q3'24, increased 11% compared to Q3'23. Q3'24 net loss of $(101) million compared to $(227) million of net loss in Q3'23. Q3'24 Adjusted EBITDA(1) of $163 million increased 55% as reported, or 53% in constant currency, compared to Q3'23. (1) See "Non-GAAP Financial Measures" below and the GAAP to non-GAAP reconciliation provided later in this release. Catalent, Inc. (NYSE:CTLT) ("Catalent"), the leader in enabling the development and supply of better treatments for patien
10-Q - Catalent, Inc. (0001596783) (Filer)
8-K - Catalent, Inc. (0001596783) (Filer)
10-K/A - Catalent, Inc. (0001596783) (Filer)
GHENT, Belgium, June 6, 2024 /PRNewswire/ -- Ardena (the "Company") today announces the retirement of Harry Christiaens, PhD and the subsequent appointment of Jeremie Trochu as Chief Executive Officer. Jeremie is a seasoned executive in the pharmaceutical Contract Development and Manufacturing Operations (CDMO) industry. Harry will step down as CEO after 20 years of leading the Company, remaining on Ardena's Board. Jeremie brings an extensive knowledge of the life sciences and CDMO industry, and a proven track record of success in the biopharma sector, with 20 years of experience in building and growing businesses globally, expanding into new markets, and leading large-scale transformations
CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new independent director to its Board. Ms. Flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management experience in the pharmaceutical services industry. She most recently served as Interim President of BioModalities at Catalent (NYSE:CTLT), a global provider of development and manufacturing solutions for drugs, biologics, cell and gene therapies and consumer heal
Traci Kyes and Makis Sigalas bring extensive industry experience to roles focused on expanding ViroCell's business in the US and Europe Team ViroCell will be attending the Cell & Gene Therapy Meeting on the Mesa, 10-12 October 2023 ViroCell Biologics ("ViroCell" or the "Company"), a specialist contract development and manufacturing organisation ("CDMO") in cell and gene therapy clinical trials, announces the appointment of Traci Kyes as Vice President (VP) of Business Development (US) and Makis Sigalas as Senior Business Development Director (Europe). Focused on driving growth in the US and Europe, respectively, Traci and Makis bring a wealth of business development expertise to ViroCel
4 - Catalent, Inc. (0001596783) (Issuer)
4 - Catalent, Inc. (0001596783) (Issuer)
4 - Catalent, Inc. (0001596783) (Issuer)
Robert W. Baird upgraded Catalent from Neutral to Outperform and set a new price target of $53.00 from $45.00 previously
Argus upgraded Catalent from Hold to Buy and set a new price target of $62.00
Wells Fargo initiated coverage of Catalent with a rating of Equal Weight and set a new price target of $43.00
The expansion increases the site's footprint by 32,000 square feet (3,000 square meters), adding storage and handling of clinical trial supply materials at controlled room temperatures between 15 and 25 degrees Celsius. It also creates space in the original building to accommodate the installation of a new, fully automatic bottle filling line, as well as a dedicated area for Catalent's FastChain® demand-led supply service. These added capabilities will support a continued high level of service to Catalent's pharma and biotech customers and the patients they serve.
RBC Capital analyst Sean Dodge reiterates Catalent (NYSE:CTLT) with a Sector Perform and maintains $63.5 price target.
Barclays analyst Luke Sergott maintains Catalent (NYSE:CTLT) with a Equal-Weight and raises the price target from $47 to $63.